France We need to raise our voice and say: look at us too, there are also mid-sized pharma companies out there looking for something different In conversation at BIO 2026 in San Diego, Frédéric Scaerou, Head of Global Business Development at Servier, explains why the company is staying disciplined rather than…
Europe Over three decades at Terumo, Takuya Hosogai has seen the Group evolve across businesses, markets and technologies. Now leading Terumo Europe, he discusses the region’s growing role in Pharmaceutical Solutions alongside its established interventional business, and how closer pharma partnerships, continuous innovation and a deeply rooted culture are shaping its…
Europe The science only matters if we can bring those therapies to the people who need them As ophthalmology enters a new era shaped by aging populations, childhood myopia and medical advances, the role of healthcare companies is evolving. For Marianthi Psaha, President and Head of EMEA and International Pricing, Market…
Korea Multi-million dollar deals, world-first approvals, and a new willingness to be patient are transforming how Korea’s biotech sector does business. Korean biotech companies want to hold onto their molecules for longer. That was the message from nearly every biotech executive PharmaBoardroom spoke with in a series of recent interviews in…
Taiwan Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI contrast agent for liver cancer, and MPT 1734, a nanomicelle-based therapy for prostate cancer, while outlining MegaPro’s partnership strategy, cell-tracking…
Korea James Park discusses Lotte Biologics’ strategy to establish itself as a global CDMO through dual manufacturing hubs in the US and Korea, advanced biologics and ADC capabilities, and a strong service-oriented culture. He outlines the company’s expansion plans, technological differentiation, and support for Korea’s emerging biotech ecosystem, while reflecting on…
UAE It takes a great deal to become number one in a field, but the harder challenge is staying there Joe Henein, CEO of Dubai-headquartered NewBridge Pharmaceuticals, has built one of MENA’s most distinctive specialty pharma platforms over the past 15 years. With over 300 people across MENA, a pan-regional footprint…
UK Drawing on a career spanning oncology drug discovery at AstraZeneca and biotech leadership as CEO of Enhanc3d Genomics, Hazel Jones is now Chief Strategy Officer at Laverock Therapeutics. We caught up with her at the Asia Summit on Global Health in Hong Kong, where the company was showcasing its programmable…
Taiwan Steve Kuo, Chairman of TRPMA, outlines Taiwan’s biotech strategy: strengthening clinical trial infrastructure, regulatory alignment and global partnerships. Drawing on experience across academia, government and diplomacy, he emphasises cultural change in trial participation and building a collaborative ecosystem, positioning Taiwan to compete globally, particularly in cell therapy and innovative drug…
Taiwan Sen Kuei Yeh, Chairman of Ta Fong Pharmaceutical, is the second-generation leader of one of Taiwan’s established domestic manufacturers. Joining in the 1990s, he assumed leadership in 2016 after gaining experience across marketing and manufacturing. Under his stewardship, Ta Fong has expanded in generics and OTC products and developed Taiwan’s…
Taiwan As SyntroMed approaches its 100-year milestone, the company is entering a decisive phase of transformation, moving beyond its established OTC foundations to build a more innovation-led and internationally connected organisation. As Dr Alexander Lin explains, from botanical oncology programmes to advanced manufacturing and a partnership-driven expansion across Asia-Pacific, the strategy…
Taiwan Promoted to General Manager of Moderna Taiwan in 2024, Wenchi Liu brings over 20 years of pharmaceutical industry experience spanning commercial strategy and operations. Since joining Moderna in 2023, she has helped position Taiwan as a priority market within the company’s Asia-Pacific region. In this interview, she discusses the rollout…
See our Cookie Privacy Policy Here
